All In Biotech

Drug Trial Radar · NCT02563041

Comparative Effectiveness of 30%TSC and Heparin Lock Solution in Hemodialysis Catheters

Comparative Effectiveness of 30% Trisodium Citrate and Heparin Lock Solutions in Preventing Infection and Dysfunction of Hemodialysis Catheters: a Randomized Controlled Trial (CITRIM Trial)

Last checked: Nov 20, 2026Latest source record: Sep 29, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 179 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

179

Actual

Start

Jul 2012

Primary completion

Jul 2014

Study completion Jul 2014

Sponsor

Lead sponsor
Catholic University of PelotasAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 29, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BACKGROUND: Central venous catheters (CVC) are the only option when hemodialysis is needed for patients without definitive vascular access. However, CVC use is associated with complications such as infection, thrombosis, and dysfunction, leading to higher mortality and expenditures. The aim of this study was to compare the effectiveness of 30% trisodium citrate (TSC30%) with heparin as CVC lock solution in preventing catheter-related bloodstream infections (CRBSI) and dysfunction in hemodialysis patients. METHODS: Randomized, double-blind controlled trial comparing the event-free survival of non-tunneled CVC locked with heparin or TSC30% in adult hemodialysis patients.

Conditions

  • Catheter Related Infection

Interventions

  • 30% TSCDrug

    The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.

  • HeparinDrug

    The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Catheter related bloodstream infectionTime frame: through study completion, an average of 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.